|
MediVas, LLC, to Present New Biopolymer Data
at the 224th Annual American Chemical Society Conference
SAN DIEGO -- March 4, 2005 -- MediVas, LLC, announced today that Dr. Huashi Zhang will present new data on its novel amino acid-based Poly(Ester Amide) copolymers (PEA) to scientists attending the 224th Annual American Chemical Society (ACS) Conference. The annual event is being held at the San Diego Convention Center from March 13 - 17, 2005. MediVas will highlight its excellent twelve month follow-up data for the First in Man clinical trial (NOBLESSE) on functionalized PEA, which revealed the safety and efficacy of the company's flagship biodegradable PEA polymer. The "programmable" nature of PEA polymers and its strong biocompatibility profile make it an excellent choice for a wide variety of drug and biologic delivery applications.
About MediVas: Since its founding in 1998, MediVas has had one simple goal - to change the way that pharmaceuticals are delivered. From small molecule drugs to whole proteins, MediVas has developed a novel platform technology that provides solutions to meet each challenge. MediVas polymers are the first of a new generation of absorbable and biocompatible drug and biologic delivery platforms. MediVas is utilizing its novel polymer technology in collaboration with some of the world's largest pharmaceutical and medical device companies, as well as our own internal product development efforts. Using this platform technology, MediVas is currently focusing its development efforts on various therapeutic areas.
Corporate Headquarters
6275 Nancy Ridge Drive
San Diego, CA 92121
T: (858) 622-2005
F: (858) 366-7301
© MediVas, LLC
|